Last reviewed · How we verify
NP137
At a glance
| Generic name | NP137 |
|---|---|
| Sponsor | Centre Leon Berard |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- NP137 Clinical and Biological Activities Assessment in Patients With Advanced/Metastatic Solid Tumors Treated by Standard Anti PD-1/PD-L1 Immunotherapies (PHASE2)
- Study Investigating the Association of NP137 With Atezolizumab-Bevacizumab Combination in First Line in Unresectable HCC (PHASE1)
- Study Investigating the Association of NP137 With mFOLFIRINOX in Locally Advanced Pancreatic Ductal Adenocarcinoma (PHASE1)
- Study of Perioperative NP137 and FOLFIRINOX in Resectable Pancreatic Cancer (PHASE1)
- Acute Myeloid Leukemia Treated With With NETrin Abs in Combination With [AZACITIDINE + VENETOCLAX] (PHASE1, PHASE2)
- GYNecological Cancers Treated with NETrin MAbs in Combination with Chemotherapy and /or Pembrolizumab (PHASE1, PHASE2)
- First in Human Evaluation of Safety, Pharmacokinetics, and Clinical Activity of a Monoclonal Antibody Targeting Netrin 1 in Patients With Advanced/Metastatic Solid Tumors (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- NP137 CI brief — competitive landscape report
- NP137 updates RSS · CI watch RSS
- Centre Leon Berard portfolio CI